Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics


Terns Pharmaceuticals, Inc. (TERN): $10.51

-0.46 (-4.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TERN Stock Price Chart Interactive Chart >

Price chart for TERN

TERN Price/Volume Stats

Current price $10.51 52-week high $28.36
Prev. close $10.97 52-week low $6.91
Day low $10.50 Volume 566,300
Day high $11.98 Avg. volume 114,187
50-day MA $10.24 Dividend yield N/A
200-day MA $0.00 Market Cap 264.13M

Terns Pharmaceuticals, Inc. (TERN) Company Bio


Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.


TERN Latest News Stream


Event/Time News Detail
Loading, please wait...

TERN Latest Social Stream


Loading social stream, please wait...

View Full TERN Social Stream

Latest TERN News From Around the Web

Below are the latest news stories about Terns Pharmaceuticals Inc that investors may wish to consider to help them evaluate TERN as an investment opportunity.

Goldman Sachs Sees These 2 Stocks Surging Over 70%

The first half of this year saw a hefty surge in consumer demand and economic growth, as people started climbing out of the COVID lockdowns. The pent-up consumer demand fueled the growth – but that’s starting to fade back a little now. The resurgence of the corona virus isn’t helping matters, even though most governments are loathe to impose further draconian lockdowns. Goldman Sachs strategist Ronnie Walker believes that the late-year economic pullback will be modest, and that strong growth will continue into 2022. He’s predicting a 5.

Michael Marcus on TipRanks | September 15, 2021

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

- TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH - Top-line TERN-201 NASH clinical data expected in 1Q 2022 FOSTER CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and oth

Yahoo | September 8, 2021

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that the Company’s management team will present at the following upcoming investor conferences in September: 2021 Virtual Wells Fargo

Yahoo | September 2, 2021

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Top-line data from ongoing Phase 1 proof of concept clinical trial of TERN-501 expected in 4Q 2021Top-line data readout from Part 1 of ongoing AVIATION Trial of TERN-201 expected in 1H 2022Cash and equivalents of $185.1 million provides runway into 2024 FOSTER CITY, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy

Yahoo | August 16, 2021

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH Sustained VAP-1 inhibition with TERN-201 may make it suitable for co-administration with other Terns therapiesTopline TERN-201 NASH clinical data expected in first half of 2022 FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecul

Yahoo | June 24, 2021

Read More 'TERN' Stories Here

TERN Price Returns

1-mo -6.08%
3-mo -31.08%
6-mo -49.10%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7791 seconds.